CURE Pharmaceutical, developer and manufacturer of the most advanced oral thin films (OTF) on the market, today announced that it will begin clinical trials in third quarter 2012 with its new anti-malaria oral thin film, PediaSUNATE(TM). PediaSUNATE(TM) is a new method and formulation of treatment for malaria, which has been tested and approved by the World Health Organization.
This new formulation of PediaSUNATE(TM) makes it is easy for caregivers to administer to children, and more importantly, is a child-friendly, tasty, oral dissolving patch (ODP) that is given by simply placing it on the tongue or cheek and allowing it to melt. No water is needed to administer the treatment. PediaSUNATE(TM) is able to make typically bitter drugs more palatable by masking the unpleasant tastes with natural products. Other non-active ingredients used in the product are either natural or derivatives of natural products.
"The devastating impact of malaria on children living around the world is a solvable problem. With PediaSUNATE(TM) we can increase efficacy and compliance in areas with no potable water," said Ed Maliski PhD, chief science office of CURE Pharmaceutical.
The packaging for PediaSUNATE(TM) is specially designed to provide the drugs with added protection from the tropical environments. In addition, the product casing employs easily identifiable colors and images to assure the age-appropriate medicines are given to the child.
CURE Pharmaceutical expects to have a commercial product available before the next malaria season begins in 2013.
No comments:
Post a Comment